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Abstract
Background:  A partial deficiency in Protoporphyrinogen oxidase (PPOX) produces the mixed disorder
Variegate Porphyria (VP), the second acute porphyria more frequent in Argentina. Identification of patients with
an overt VP is absolutely important because treatment depends on an accurate diagnosis but more critical is the
identification of asymptomatic relatives to avoid acute attacks which may progress to death.
Methods: We have studied at molecular level 18 new Argentinean patients biochemically diagnosed as VP. PPOX
gene was amplified in one or in twelve PCR reactions. All coding exons, flanking intronic and promoter regions
were manual or automatically sequenced. For RT-PCR studies RNA was retrotranscripted, amplified and
sequenced. PPOX activity in those families carrying a new and uncharacterized mutation was performed.
Results: All affected individuals harboured mutations in heterozygous state. Nine novel mutations and 3 already
reported mutations were identified. Six of the novel mutations were single nucleotide substitutions, 2 were small
deletions and one a small insertion. Three single nucleotide substitutions and the insertion were at exon-intron
boundaries. Two of the single nucleotide substitutions, c.471G>A and c.807G>A and the insertion (c.388+3insT)
were close to the splice donor sites in exons 5, 7 and intron 4 respectively. The other single nucleotide
substitution was a transversion in the last base of intron 7, g.3912G>C (c.808-1G>C) so altering the consensus
acceptor splice site. However, only in the first case the abnormal band showing the skipping of exon 5 was
detected. The other single nucleotide substitutions were transversions: c.101A>T, c.995G>C and c.670 T>G that
result in p.E34V, p.G332A and W224G aminoacid substitutions in exons 3, 10 and 7 respectively. Activity
measurements indicate that these mutations reduced about 50% PPOX activity and also that they co-segregate
with this reduced activity value. Two frameshift mutations, c.133delT and c.925delA, were detected in exons 3
and 9 respectively. The first leads to an early termination signal 22 codons downstream (p.S45fsX67) and the
second leads to a stop codon 5 codons downstream (p.I309fsX314). One reported mutation was a missense
mutation (p.G232R) and 2 were frameshift mutations: c.1082insC and 1043insT. The last mutation was detected
in six new apparently unrelated Argentinean families.
Conclusion: Molecular analysis in available family members revealed 14 individuals who were silent carriers of
VP. Molecular techniques represent the most accurate approach to identify unaffected carriers and to provide
accurate genetic counselling for asymptomatic individuals. The initial screening includes the insertion search.
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Background
The hereditary porphyrias are a group of diseases resulting
from genetically determined partial deficiencies in one of
the heme biosynthetic enzymes. These disorders can be
classified on the basis of their clinical manifestations into
cutaneous, acute and mixed porphyrias. Variegate Porphy-
ria (VP) (MIN # 176200) is an autosomal dominant dis-
order associated with a deficiency of the penultimate
enzyme of the heme biosynthetic pathway [1-3] the Pro-
toporphyrinogen oxidase [PPOX; EC 1.1.3.4, Genebank
accession number X99450.1] which catalyses the six-elec-
tron conversion of Protoporphyrinogen IX to Protopor-
phyrin IX (PROTO IX) (Figure 1)
Patients with VP may manifest a broad spectrum of clini-
cal manifestations characterized by cutaneous photosen-
sitivity and neurological symptoms which can occur
separately or together in affected individuals. Cutaneous
photosensitivity is characterized by skin fragility, ero-
sions, blisters, millia and pigmentary changes in sun-
exposed areas. Neurological symptoms include intermit-
tent attacks of abdominal pain, constipation, vomiting,
hypertension, tachycardia, fever and various peripheral
and central nervous system manifestations. Acute attacks
may frequently result from exposure to diverse porphyri-
nogenic drugs, alcohol ingestion, reduced calories intake
due to fasting or dieting, infections and hormones which
stimulate heme synthesis by δ-aminolevulinic acid syn-
thase (ALA-S) induction thereby increasing the produc-
tion of the porphyrin precursors ALA and
porphobilinogen (PBG) [3-5].
Biochemical features of VP include increased biliary excre-
tion of coproporphyrinogen and protoporphyrinogen
and their corresponding porphyrins, commonly meas-
ured as fecal porphyrins. The standard biochemically tests
for VP diagnosis involve quantification and chromato-
graphic separation of fecal porphyrins, urine and plasma
Heme biosynthetic pathway, enzymes involved and associated porphyries Figure 1
Heme biosynthetic pathway, enzymes involved and associated porphyries.BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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porphyrin analysis. Urine ALA and PBG are also measured
for confirmation of an acute attack and for exclusion of
other forms of Porphyria. In asymptomatic individuals,
urine ALA, PBG and porphyrins were within the reference
values, however stool porphyrins used to be elevated even
in remission [4,6-8].
VP is an autosomal dominant disorder with incomplete
penetrance, with heterozygous individuals exhibiting an
approximately 50% reduced PPOX activity [1,2]. How-
ever, since the first description of a homozygous VP case
in 1984 [9] several true homozygous and compound het-
erozygous cases have been reported [8,10-16].
Identification of patients with an overt VP is important
because treatment depends on an accurate diagnosis but
more critical is the identification of asymptomatic rela-
tives, because with the proper education about avoiding
porphyrinogenic drugs as well as known triggering factors,
acute attacks which may progress to death, can be
reduced. Although plasma porphyrin index (PPI) is a
more sensitive and specific test for VP diagnosis than fecal
porphyrin analysis, neither test is sensitive enough for
children diagnosis and both are less sensitive in asympto-
matic carriers than in symptomatic patients [17]. So, DNA
analysis remains the preferred method for the accurate
detection of latent carriers of VP trait and thereby facili-
tates councelling so that precipitating factors can be
avoided, as already indicated.
The 5 kb PPOX gene is localized on chromosome 1q2.2-
2.3 and contains one non-coding and 12 coding exons
[18-20]. Human cDNA encoding PPOX has been cloned
and sequenced [21]. Sequence analysis revealed that
PPOX consists of 477 aminoacids with a calculated
molecular mass of 50.8 kDa. Northern blot analysis
revealed the synthesis of a 1.8 Kb mRNA for PPOX [21].
So far, about 130 different mutations were identified in
the PPOX gene causing VP [22]. Mutations in the PPOX
gene are heterogeneous and most of them are unique to
individual families. The only exception is the missense
mutation R59W which is present in about 96% of all
South African patients with VP due to a well documented
founder effect, so it has been identified as the molecular
basis for the high prevalence of VP in Afrikaner popula-
tion [23-26]. The mutation 1329delTACAC has also been
reported as a founder mutation in Chilean population
[27].
In the first genetic study of the porphyrias in South Amer-
ica we had described 3 new mutations and 2 previously
reported in 6 Argentinean patients with VP [28-30]. In this
study, in 18 apparently non-related VP patients, we found
4 new splicing defects, 3 new missense mutations and 2
new small deletions. In other two families 2 previously
reported mutations were found. In addition, the mutation
1043insT, previously described for 4 Argentinean VP fam-
ilies [28,30] was now found in 6 new unrelated VP fami-
lies.
Methods
Patients
Informed consent was obtained from all patients prior to
their inclusion in the study and the study protocol was
approved by the Ethical Committee of the Centro de
Investigaciones sobre Porfirinas y Porfirias (CIPYP – Hos-
pital de Clínicas, CONICET).
Fourteen female and 4 male apparently unrelated Argen-
tinean patients were studied. All of them had current
symptoms of VP and the diagnosis was made on the basis
of their clinical history of at least one acute attack and/or
typical cutaneous lesions associated with increased excre-
tion of porphyrins in urine and faeces. The chromato-
graphic profile of fecal porphyrins and plasma porphyrin
index (PPI) were determined. All of these biochemical
parameters were measured in each patient and available
relatives by the methodology already described [31]. For
PPI determination 1 ml of heparinized fresh blood was
centrifuged at 2000 rpm for 10 minutes, 0.3 ml of the
plasma were diluted with PBS (1:10) and its fluorescence
was spectrofluorometrically determined. PPI was the ratio
between the maximum intensity at 626 nm and that of the
baseline at the same wavelength [31]. The final diagnosis
of the patients was established by genetic studies. The
mode of VP presentation (skin lesions alone, acute attacks
alone, or both together) was recorded in all symptomatic
patients. Unrelatedness was determined by family inquir-
ies, none of the patients were known to be related. All
patients and available relatives, their clinical and bio-
chemical symptoms present at the age of diagnosis and
the carrier status are shown in Table 1.
Protoporphyrinogen oxidase activity
PPOX activity was determined following the methodolo-
gies described by Brenner and Bloomer [1] and Deybach
et al [2].
Identification of mutations
DNA isolation and PPOX gene amplification
Genomic DNA was extracted from peripheral blood leu-
kocytes using the GFX Genomic Blood DNA Purification
Kit (Amersham) according to the manufacture's instruc-
tions. Exons 1–13 along with 50–100 bp of their flanking
regions, intronic and promoter regions of the PPOX gene
of each symptomatic VP patient were amplified in one or
eleven different PCR reactions by means of the primers
and conditions listed in Table II. Standard reaction mix-
ture contained in a final volume of 50 μl: buffer 1×,BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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Table 1: VP Argentinean families: biochemical and molecular data
Urine
Family Sex Age ALA
(mg/24 h)
PBG 
(mg/24 h)
PORPH 
(ug/24 h)
Blood IPP Fecal Porph 
(ug/w)
Symp 
(C/A)
Mutation/Defect
I P F 35 2.4 2.9 1212 8.80 896 +/- c.471G>A/del exon5
M F 64 1.2 1.1 120 1.21 (619) 70 -/- c.471G>A/del exon5
F M 64 1.4 1.1 77 1.10 (619) 80 -/- -------
Si F 27 1.2 2.4 1975 9.20 371 +/- c.471G>A/del exon5
II P F 45 4.8 6.9 1510 9.71 659 +/+ c.807 G>A/r.spl?
III P F 35 9.2 21.6 4032 7.80 485 +/+ c.808-1G>C/r.spl?
C F 28 1.1 0.8 97 1.70 127 -/- c.808-1G>C/r.spl?
C F 33 ND ND ND ND ND -/- c.808-1G>C/r.spl?
IV P F 40 2.5 4.2 1814 6.50 2078 +/+ c.338+3insT/r.spl?
V P F 26 1.3 1.6 149 10.40 2411 +/- c.101A>T/p.E34V
Si F 31 1.2 2.1 539 6.00 1208 +/- c.101A>T/p.E34V
VI P F 16 8.0 18.5 2619 10.12 ND -/+ c.101A>T/p.E34V
VII P F 28 2.0 1.9 948 8.00 428 -/+ c. 995 G>C/pG332A
F M 60 1.6 2.0 30 1.12 (619) 78 -/- c. 995 G>C/pG332A
D F 8 0.6 0.9 82 1.10 (619) 85 -/- -------
Si F 25 2.6 2.0 5 2.28 271 -/- c. 995 G>C/pG332A
A F 57 1.7 2.2 52 4.27 52 -/+ c. 995 G>C/pG332A
C F 21 0.6 0.9 30 1.24 (619) 79 -/- -------
C F 15 1.2 0.9 40 1.28 (619) 85 -/- c. 995 G>C/pG332A
A F 89 ND ND ND ND ND -/- -------
VIII P F 40 2.4 4.2 874 5.50 1030 +/+ c.670T>G/p.W224R
D F 17 1.4 1.3 2 1.30 (619) ND -/- -------
D F 15 0.9 1.4 34 1.28 (619) ND -/- c.670T>G/p.W224R
A F 45 2.5 2.3 450 11.77 893 +/+ c.670T>G/p.W224R
C F 23 1.4 1.5 25 1.06 (619) 307 -/- -------
IX P M 49 1.8 1.8 2291 10.00 2102 +/- c.133delT/S45fsX67
X P F 28 1.4 2.6 330 13.5 688 +/+ c.925delA/p.I309fsX314
XI P F 37 1.2 3.2 801 12.6 1314 -/+ C.694 G>C/G232R
XII P M 29 6.5 7.7 765 4.60 250 -/+ c.1082insC/p.S359fsX377
Si F 35 3.6 3.2 742 4.20 230 -/+ c.1082insC/p.S359fsX377
D F 16 0.5 1.4 25 1.30 ND -/- -------
Ni F 18 1.1 2.1 158 1.30 (616) ND -/- c.1082insC/p.S359fsX377
XII P F 38 1.6 2.7 985 5.50 2913 +/+ 1043InsT/Y348fsX349
XIV P M 29 2.3 9.0 2375 7.25 1197 +/- 1043InsT/Y348fsX349
XV P M 24 4.9 3.3 1355 17.50 2141 +/- 1043InsT/Y348fsX349
B M 23 ND ND ND 2.16 ND -/- 1043InsT/Y348fsX349
Si F 31 ND ND ND 1.20 (619) ND -/- -------
XVI P F 39 12.7 36.3 1202 9.22 936 +/+ 1043InsT/Y348fsX349
XVII P F 28 8.9 14.5 3502 5.30 1739 +/+ 1043InsT/Y348fsX349
XVIII P F 28 5.7 24.0 3527 13.50 ND -/+ 1043InsT/Y348fsX349
XIX P F 37 6.1 8.7 1321 11.50 964 +/- 1043InsT/Y348fsX349
D F 10 1.2 1.5 87 1.25 ND -/- 1043InsT/Y348fsX349
D F 13 1.4 1.1 65 1.23 ND -/- -------
So M 6 1.0 ND 64 1.30 (618) ND -/- -------
Si F 34 ND ND ND 1.18 (618) ND -/- 1043InsT/Y348fsX349
XX P F 33 2.0 4.0 1045 8.80 616 +/- 1043InsT/Y348fsX349
M F 59 1.5 3.1 390 7.30 515 +/- 1043InsT/Y348fsX349
D F 13 1.3 2.0 96 1.30 92 -/- -------
So M 8 ND ND ND ND ND -/- -------
B M 29 ND ND ND ND ND -/- -------
XXI P F 50 1.3 2.3 2364 6.00 1376 +/+ 1043InsT/Y348fsX349
XXII P F 29 1.5 3.7 317 11.20 1329 +/- 1043InsT/Y348fsX349
M F 60 1.2 2.0 26 1.25 (619) 36 -/- -------
D F 17 ND ND ND ND ND -/- 1043InsT/Y348fsX349
D F 16 ND ND ND ND ND -/- -------
Si F 22 1.4 2.0 67 1.25 (619) ND -/- 1043InsT/Y348fsX349BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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dNTP's 200 μM, TAQ DNA polymerase (Recombinant or
Platinum High Fidelity, Invitrogen), primers 0, 5 μM and
variable amounts of Mg++ according to the fragment to be
amplified as it indicated in Table II. PCR amplified double
stranded DNA was purified either using the QIAQuick
PCR purification kit (QIAGEN) or from agarose gels by
means of Nucleospin Extract kit (Machery-Nagel) or
S.N.AP™ Gel Purification Kit (Invitrogen).
Sequencing analysis
Mutations screening was done by manual sequencing
employing the Amplicycle Sequencing kit (Applied Bio-
systems, Roche) or fluorescent automated sequencing in
the forward and reverse directions. In the first case the
products were analysed in a 8% polyacrylamide gel in the
presence of 6 M UREA. Sequencing primers were chosen
to include 50–100 bp of flanking regions and sequences
were analysed by visual inspection comparing with the
normal sequence [20,21]. All mutations were confirmed
by sequencing both DNA strands of at least two different
PCR products. To validate the new mutations their
absence in 50 control individuals by manual or auto-
mated sequencing has been performed.
RNA Analysis
RNA was isolated using the RiboPure™ Blood kit
(Ambion) and was reverse transcribed in a final volume of
20 μl. To 1 μg of denaturated RNA, 1× first strand buffer,
300 μM each dNTP, 0,025 μg oligo dT, 10 μM DDT and
400 units of murine retrotranscriptase (Invitrogen) were
added and RT was performed at 37°C for 1 hour with the
corresponding primers and the protocol according to the
fragment to be amplified depending on the splicing muta-
tion found (Table 2).
Analysis of missense mutations
The role of the aminoacids involved in the missense muta-
tions in the crystallographic structure of the PPOX protein
was evaluated according Koch et al [32] and the deleteri-
ous consequences of their replacement for the mutant res-
idues were analised by Swiss PDBViewer program [33].
Numbering system
Exonic nucleotides were numbered from the first nucle-
otide of the translation-initiation codon according to the
cDNA sequence derived from PPOX genomic sequence
while promoter and intronic nucleotides were numbered
according to the complete PPOX genomic sequence
[Genebank asccession number X99450.1].
Databases
The Human Gene Mutation Database [22] was used for
information about reported mutations in the PPOX gene.
Results
Sequencing analysis of the coding regions and their flank-
ing regions of the DNA from 18 unrelated new patients
with VP revealed 9 new mutations and 3 previously iden-
tified mutations (Table 1). From the 9 novel mutations 6
were single nucleotide substitutions, 2 were single nucle-
otide deletions and one was a small insertion.
Three single nucleotide substitutions and the small new
insertion were at exon-intron boundaries regions. Two
Si F 35 1.1 1.5 38 1.06 (619) ND -/- -------
Si F 35 3.2 2.4 529 1.60 (619) 548 +/- 1043InsT/Y348fsX349
Ni F 15 ND ND ND 5.33 ND -/- 1043InsT/Y348fsX349
Ni F 10 ND ND ND 1.90 ND -/- 1043InsT/Y348fsX349
Ni F 15 ND ND ND 1.28 (619) ND -/- -------
C F 42 2.2 1.9 47.5 1.25 46 -/- -------
XXIII P F 24 6.4 8.2 1108 7.10 1529 +/+ c.503G>A/p.R168H
So M 18 1.1 1.2 35 1.15 (619) ND -/- c.503G>A/p.R168H
So M 16 2.0 1.5 31 1.02 (619) ND -/- -------
So M 19 0.9 0.6 86 120 ND -/- c.503G>A/p.R168H
Si F 35 ND ND ND 3.15 1281 +/- c.503G>A/p.R168H
XXIV P F 4 2.8 6.2 488 7.00 1705 +/- C.745delG/V251fsX272
M F 30 1.9 2.9 65 3.20 563 +/- C.745delG/V251fsX272
A F 28 3.0 2.0 114 5.33 2491 +/- C.745delG/V251fsX272
XXV P F 27 3.1 4.0 870 5.40 1592 +/- c.532T>G/p.L178V
XXVI P F 39 4.4 6.2 307 5.33 1214 +/- c.317A>C/p.H106P
Clinical and biochemical symptoms at the age of diagnosis, as well as the presence or absence of mutation in the PPOX gene, for all the Argentinean 
VP patients and the available relatives studied at molecular level are shown. Methodology was as described by Batlle et al, 1997 (30). Normal values 
were: ALA: 2–4 mg/24 h; PBG: 1–2 mg/24 h; urinary porphyrins: up to 250 μg/24 h; faecal porphyrins: up to 130 μg/dw; PPI: up to 1.30 at λ = 618. 
P: proband, M: mother, F: father, Si: sister, B: brother, D: daughter, So: son, A: aunt, C: cousin, Ni: niece. Probands of the families XIX to XXVI have 
been previously studied. All families that carried the 1043insT (families to XIII to XXI) are shown.
sAcute symptoms included abdominal pain, paresthesia, muscle weakness, paralysis and/or data of at least one acute attack. Cutaneous symptoms 
included blisters, erosions, scaring in sun exposed areas and hyperthricosis. Probands of the families XII, XIII and XVI came first with only cutaneous 
symptoms but they have also clinical data of neurological manifestations.
Table 1: VP Argentinean families: biochemical and molecular data (Continued)BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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single nucleotide substitutions (Probands I and II) were G
to A transitions in the last bases of exon 5 (c.471G>A)
(Figure 2a) and exon 7 (c.807 G>A) (Figure 3a) which do
not lead to an aminoacid change but were close to the
donor consensus splice sites between exon 5 and intron 5
and between exon 7 and intron 7 respectively and so, they
might affect splicing. However, although this base is a res-
idue about 70% conserved for splicing [34] and both
changes were absent in 50 normal individuals, only for
the first case an abnormal band showing the skipping of
exon 5 could be detected (Figure 2b,c). The other single
nucleotide substitution (Proband III) was a G to C trans-
version in the last base of intron 7 (g.3912 G>C) (Figure
3b) which destroys the splice acceptor site between intron
7 and exon 8 (c 808-1 G>C) and is expected to affect nor-
mal splicing. Although this is a 100% conserved residue
for splicing [32] and this change was absent in 50 control
subjects, RT-PCR studies again failed to demonstrate an
abnormal band in the RNA's patient. However in both of
these cases the value of PPOX activity was about 40% of
normal value (Table 3). The other mutation which is very
likely to affect the mRNA splicing was a T insertion in
intron 4 (g.1742insT), in the boundary of splice donor
site between exon 4 and intron 4 (c.338+3insT) (Figure
4). This was the only change found in this patient
(Proband IV) and it was also absent in 50 controls. More-
over, activity enzyme in this patient was about 40% of the
control (Table 3)
The other 3 new single nucleotide substitutions were
transversions leading to an aminoacid change. One was
an A to T substitution at nucleotide position 101
(c.101A>T) (Proband V and VI, Figure 5) which results in
a missense mutation that changes a glutamic acid residue
to a valine residue in exon 3 (p.E34V). The other was a G
to C substitution at nucleotide position 995 (c.995 G>C)
(Proband VII, Figure 6) which results in a missense muta-
tion that changes a glycine residue to a alanine residue in
exon 10 (p.G332A). The last one was a T to G change at
nucleotide position 670 (c.670T>G) leading to a tryp-
tophan to a glycine substitution (p.W224G) (Proband
VIII, Figure 7). These mutations were present in the symp-
tomatic relatives studied (Table 1) and they were absent in
50 control individuals. Moreover, PPOX activity studies
showed that the enzyme activity was reduced to a value of
Table 2: Primers and conditions used for PPOX gene and cDNA amplification
Amplified 
region (exon)
Amplified Region 
(intron)
MW (pb) Sequence (5' to 3') Annealing (°C) Mg+2 (mM)
I 2, 3, 4 2, 3 758 F: GCTTCTGGAGCGCAGGTTGTCC
R: AAGGCATATGAGGATGAGGGCA
60 1.6
II 5, 6 5 680 F: AGGTATGTCAGGAGCTTCCCCC
R: CCCTCACTTTGGCAGTACTTAA
60 1.6
III 7, 8 7 852 F: TGCTGGGATTACAGGTGT
R: AGCTTTTGCTTCTCACTGGTAGG
62 2.5
IV 9 ----------- 321 F: GATTACAGGTGTGAGCCACCA
R: CCTACCAGTGAGAAGCAAAAGCT
60 2
V 10, 11,12, 13 10,11,12 13 859 F: GCCCTTTCCTTCTGACGCATG
R: GCCAGACCAAGCCAAGCCAAGC
62 2.5
VI 1 1 440 F: CCAAGTCCCGCCAATCCAGAT
R: GGACAACCTGCGCTCCAGAAGC
60 5
VII Promotor ----------- 705 F: AGGTGATAGAGAACTGGCCCAA
R: CAGCCTTTTCGGTCTCTCCTA
63 3
VIII ------------ 4 786 F: TCTGAGCTTGGCTTGGATTC
R: CTCTGCAGCTGGTTTAGG
60 2
IX ------------ 6 528 F: GCTTTCCCAGTCTCTTCC
R: AAGGCCTGGCGAATGAGT
60 2
X ------------ 8 313 F: ATTCTCATTTTCTGGGTCTCTC
R: TCAGCAGGGAGCAGCTCACTG
60 2
XI ------------ 9 535 F: CTGAGTGCCATCACTGCA
R: GCTCAGGGAAAGCAACTG
60 2
XII Gen All 5,500 F: AGAGAACTGGCCCAAAATTGGAGT
R: CAGACCAAGCCAAGCCAAGCAATT
60 2
4–9 From nt 226 (exon 4) to nt 893 (exon 9). 668 F: TCTGAGCTTGGCTTGGATTC
R: GTCACTCGACGAGGGACGACT
60 3
6–9 From nt 478 (exon 6) to nt 893 (exon 9). 416 F: TCTCTAGCCATGGACAGTCT
R: GTCACTCGACGAGGGACGACT
60 6
All primers were developed in the course of this study. Primers I to XII were used for DNA amplification and primers 4–9 and 6–9 were used for 
cDNA amplification.BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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about 50% in both these patients and their asymptomatic
relatives (Table 3).
The other 2 new mutations were frameshift mutations
which produce an early stop codon. One of them was a
timine deletion at nucleotide 133 in exon 3 (c.133delT),
(Proband IX, Figure 8) resulting in a frameshift at ami-
noacid 45 with a premature stop codon 22 codons down-
stream (p.S45fsX67). The other was an adenine deletion
at nucleotide 4215 in exon 9 (Proband X, Figure 9) result-
ing in a frameshift at aminoacid 309 (c.925delA) with a
premature stop codon 5 codons downstream
(p.I309fsX314).
In other two families, 2 previously described mutations
were found. One was a missense mutation, G232R in
exon 7 (Table 1, Proband XI), already published by Dey-
bach et al [35] and D'Amato et al [36]. The other was the
insertion 1082insC in exon 10 (Table 1, Proband XII)
which results in a frameshift at aminoacid 359 with a pre-
mature stop codon 18 codons downstream
(p.S359fsX377), so introducing 18 novel amino acids
[37-39].
In addition, six new families (Table 1, Probands XIII to
XVIII) carrying the mutation c.1043insT previously
described for another four unrelated Argentinean VP
a) c.471 G> A mutation in the last base of exon 5; b) 4% agarose gel of normal and mutant alleles of the cDNA from the patient  showing an extra band of about 530 bp Figure 2
a) c.471 G> A mutation in the last base of exon 5; b) 4% agarose gel of normal and mutant alleles of the cDNA from the 
patient showing an extra band of about 530 bp. N = Normal, P: patient; NA: normal allele; MA: mutant allele; M: marker 100 
bp; c) Sequencing gels for the normal and mutant patient cDNA showing the skipping of exon 5.BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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patients [28,30] were found (Figure 10). This mutation
produces a frameshift at aminoacid 348 and a premature
stop codon, 1 codon downstream the inserted nucleotide
(p.Y348fsX349).
Discussion
The elucidation of PPOX nucleotide sequence allowed the
detection and characterization of several mutations in this
gene associated with VP and since then genetic analysis is
the most reliable and accurate methodology for confirmig
the diagnosis and most importantly for latent carriers
identification.
To date, 72 individuals, belonging to 57 apparently unre-
lated Argentinean families have been biochemically diag-
nosed as VP and the analysis of the biochemical data
obtained for all these families studied in our Centre
showed that the prevalence for this population is about
1:600,000 as previously reported [30], which is very low
when compared with others [23-25,37,40].
As it is shown in Table 3, 20 patients (28%) presented
only acute symptoms, a value close to that reported by
von und zu Fraunberg et al [40] for patients from Finland
(29%) before 1980. Moreover, we have 25 patients with
only cutaneous symptoms (35%), close to the value also
reported by von und zu Fraunberg et al [40] for the Finish
population (42%) but at variance with those reported for
Western Europe (59%) [37] and for the South African
population before (52%) [41] and after 1980 (91%) [42].
It is of note that the percentage of patients with both
symptoms (37%) is higher than the value found by What-
ley et al [37] and much higher than those found for the
Finish [40] and South African populations [41,42] but
smaller than our own previous results (50%) [30].
a) transition G> A in the last base of exon 7 (c: 807G>A and b) transversion G> C in the last base of intrón 7 (c. 808-1 G>C) Figure 3
a) transition G> A in the last base of exon 7 (c: 807G>A and b) transversion G> C in the last base of intrón 7 (c. 
808-1 G>C).BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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Until now, 52 individuals representing these 26 appar-
ently unrelated Argentinean families have been studied at
the molecular level. In Table 1 the clinical symptoms, bio-
chemical findings and the mutation detected for all the
new and previously described patients [28-30] as well as
all the available relatives are shown. Molecular analysis in
those available family members revealed that 15 individ-
uals were silent carriers of VP. This is very important for
our VP population since PPI, the most reliable biochemi-
cal method to detect VP, was positive in only 5 of them
(67%). Besides most of the asymptomatic carriers with a
negative plasma peak were under 20 years, as it has been
previously found by Hift et al [42]. The number of asymp-
tomatic carriers detected (about 29%), is still much lower
than the values reported by others [37,40-42] but unfor-
tunately higher than our own previous results (15%) for
the Argentinean population [30]. These results suggest
that much work is yet to be done for the Argentinean pop-
ulation to become aware of the vital importance of molec-
ular studies to confirm a putative diagnosis of VP and to
detect silent carriers of the porphyria in affected families
to prevent the development of the disease.
In this study, in 18 apparently unrelated Argentinean fam-
ilies 9 new mutations have been identified (Table 1). Four
of them are expected to inactivate normal splicing sites
and so they are likely to affect the normal splicing of the
mRNA. Three of them were single nucleotide substitu-
tions, c.471G>A, c.807 G>A and c.808-1G>C and the
other was a small insertion. In effect, they might produce
the skipping of the exon, retention of all or part of the
intron or the activation of a cryptic splicing site [34].
However, only for the c.471G>A mutation (Figure 2a),
which affects the donor splicing site for intron 5, the
mutant band could be detected indicating exon 5 skipping
(Figure 2b, c). For the other 2 mutations, although it is
very probably that produce an aberrant splicing because
they affect conserved bases for splicing [34], only the nor-
mal band could be detected in RT-PCR studies. It would
be very likely that in these cases the transcripts resulting
from the abnormal splicing were so unstable to be
detected and they would be degraded by the so-called
nonsense-mediated mRNA decay [43,44].
Other 3 single nucleotide substitutions were transversions
leading to missense mutations, c.101A>T, c.670 T>G and
c.995G>C in exons 3, 7 and 10 respectively. They were
also present in the symptomatic relatives studied and they
were absent in 50 healthy controls and thereby it was
unlikely to be a common polymorphism. These changes
would either give rise to specific aminoacid substitutions
at protein level or would affect an exonic splicing
enhancer (ESE's) that would exert deleterious effects on
a) Normal sequence and b) Insertion of a T at the nucleotide  position 338+3 Figure 4
a) Normal sequence and b) Insertion of a T at the 
nucleotide position 338+3.
Table 3: Protoporphyrinogen oxidase activity
Family Patient Total activity nmoles PROTO/mg protein/h PPOX activity (%) Mutation/Defect
II P 16.28 43 c.807 G>A/r.spl?
III P 13.15 39.55 c.808-1G>C/r.spl?
C 15.58 46.85 c.808-1G>C/r.spl?
C 16.85 50.67 c.808-1G>C/r.spl?
IV P 14.35 42.56 c.338+3insT/r.spl?
V P 18.48 55.58 c.101A>T/p.E34V
VII P 15.84 47.64 c. 995 G>C/pG332A
F 16.89 50.79 c. 995 G>C/pG332A
C 19.21 57.77 c. 995 G>C/pG332A
VIII P 16.95 50.98 c.670T>G/p.W224R
D 18.12 54.19 c.670T>G/p.W224R
PPOX activity was determined as described in Materials and Methods. The values are the mean value of two determinations run in duplicates.
The patients are the probands of the families indicated in Table 1. PPOX activity values of the clinical and biochemical asymptomatic relatives from 
these families are shown. Normal value: 33.25 ± 6.32 nmoles PROTO/mg protein/h.
P: proband; F: father; D: daughter; C: cousinBMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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a) Normal sequence and b) Transversion A> T in the nucleotide 101 of exon 3 (E34V) Figure 5
a) Normal sequence and b) Transversion A> T in the nucleotide 101 of exon 3 (E34V).
a) Normal sequence and b) Transversion G> C in the nucleotide 995 in exon 10 (G332A) Figure 6
a) Normal sequence and b) Transversion G> C in the nucleotide 995 in exon 10 (G332A).BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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a) Normal sequence and b) Transversion T > G in the nucleotide 670 in exon 7 (T670G) Figure 7
a) Normal sequence and b) Transversion T > G in the nucleotide 670 in exon 7 (T670G).
a) Normal sequence and b) Deletion of a T at the nucleotide position 133 Figure 8
a) Normal sequence and b) Deletion of a T at the nucleotide position 133.BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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a) Normal sequence and b) Deletion of a A at the nucleotide position 925 Figure 9
a) Normal sequence and b) Deletion of a A at the nucleotide position 925.
a) Normal sequence and b) Insertion of a T at the nucleotide position 1043 Figure 10
a) Normal sequence and b) Insertion of a T at the nucleotide position 1043.BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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the mRNA level by interfering with normal splicing [45-
48]. However, the latter possibility seems to be unproba-
ble in these cases. In the p.E34V and p.W224G mutations
the glutamic acid and the tryptophan residues are not
involved in one of the ESE's sequences predicted for
human PPOX [50] In the other case, the p.G332A muta-
tion, although the glycine residue is in fact involved in
one of the ESE's sequences predicted for this enzyme
(RESCUE-ESE) [49], RT-PCR studies carried out from
patient's RNA showed only the normal band suggesting
that these base change in this ESE's sequence would not
alter the normal splicing of the pre-mRNA.
On the other hand, multiple aminoacid sequence align-
ment of eukaryotic PPOXs, revealed that mutations
p.E34V and p.G332A affect residues that are conserved in
mitochondrial PPOX2 from Nicotiana tabacum and Arabi-
dopsis thaliana and chloroplast PPOX1 from Nicotiana tab-
acum [32] and also in eucaryotes such as mouse, rat and
monkey indicating an important role for both aminoacid
residues in the enzyme. In fact, in the crystallographic
structure for the enzyme from Nicotiana tabacum pub-
lished by Koch et al [32], E34 residue (E43 for the plant
enzyme) lies in the highly conserved FAD-binding
domain and the extra carboxyl group is interacting with
the cofactor. So, its replacement for a neutral aminoacid
would very likely interfere with this interaction [33], so
reducing protein activity. On the other hand, G332 (G554
in the plant enzyme) is one of the residues involved in the
binding of the inhibitor INH used to model the binding
of PROTOgen IX and Proto IX in the crystallographic
structure for the enzyme from Nicotiana tabacum pub-
lished by Koch et al [32] and so, this mutation is also
likely affecting activity.
The last missense mutation, p.W224G affects a residue
which is absent in the crystallographic structure of Nico-
tiana Tabacum [32] but it is conserved in different mam-
malian such as mouse and monkey. This tryptophan
residue seems to play a very important role in the protein
activity since it was involved in other two already
described mutations causing VP: p.W224X [37] and
p.W224R [39]. Recently was also suggested that this ami-
noacid would likely be in the internal mitochondrial sig-
nal targeting [50-52].
Two novel small deletions were detected. One of them
was a T deletion, c.133delT in exon 3 introducig 22 novel
amino acids before the premature stop codon
(p.S45fsX67). The other was an A deletion, c.925delA
leading to a stop codon 5 codons downstream
(p.I309Sfs314X). Both mutations would produce unsta-
ble mRNA's or truncated proteins.
In all cases where the mutation was new and has not been
characterized (missense and splicing mutations), enzyme
activity values for these patients were such that they rein-
forced our hypothesis, indicating that these mutations are
the disease causing mutations in our VP patients (Table
3). Moreover, PPOX activity values for the clinical and
Table 4: Clinical features analysis
N° (%) Subjects 
from
Symptomatology Present Study 
(n: 72)
South Africaa
 (n: 269)
Souh Africab (n: 11) Western Europe c 
(n: 103)
Finlandd
Before 1980 (n: 34) After 1980 (n: 20)
Acute 20 (28) 51 (19) 0 (0) 20 (20) 10 (29) 3 (15)
Cutaneous 25 (35) 156 (58) 10 (91) 61 (59) 14 (42) 13 (65)
Both 27 (37) 62 (23) 1 (9) 22 (21) 10 (29) 4 (20)
Asymptomatic 15 (29) 31 (10) 17 (61) ---------- 19 (36) 30 (60)
Acute 20 (28) 51 (19) 0 (0) 20 (20) 10 (29) 3 (15)
Cutaneous 25 (35) 156 (58) 10 (91) 61 (59) 14 (42) 13 (65)
Both 27 (37) 62 (23) 1 (9) 22 (21) 10 (29) 4 (20)
Asymptomatic 15 (29) 31 (10) 17 (61) ---------- 19 (36) 30 (60)
Acute 20 (28) 51 (19) 0 (0) 20 (20) 10 (29) 3 (15)
Cutaneous 25 (35) 156 (58) 10 (91) 61 (59) 14 (42) 13 (65)
Both 27 (37) 62 (23) 1 (9) 22 (21) 10 (29) 4 (20)
Asymptomatic 15 (29) 31 (10) 17 (61) ---------- 19 (36) 30 (60)
The total number of symptomatic subjects were considered
a: Eales et al (1980), b: Hift et al, 2004, c: Whatley et al, 1999, d: von und zu Fraunberg et al, 2000.BMC Medical Genetics 2008, 9:54 http://www.biomedcentral.com/1471-2350/9/54
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biochemical asymptomatic relatives from these families,
indicate that the mutation co-segregates with the 50%
enzyme activity (Table 3).
Three already described mutations were also found. One
was a missense mutation, p.G232R [34,35]. The other 2
reported mutations were frameshift mutations. One of
them was a C insertion in the streach of 6 Cs in exon 10
(c.1077-1082insC), which had been previously described
by D'Amato et al [36] and Whatley et al [37]. This same
mutation was recently described for the Swiss [38] and
Spanish [39] populations. It is of note that while Whatley
et al [37] and Lecha et al [39], found this mutation associ-
ated with only cutaneous symptoms, the Argentinean
family carrying this mutation presents both symptoms as
it has been described by Schneider-Yin et al for the Swiss
patients [38]. Moreover the E34V mutation was found in
two Argentinean unrelated families, one with only cutane-
ous symptoms (Proband V) and the other with only acute
symptoms (Proband VI). These results suggest that no cor-
relation would seem to exist between clinical features and
the type of mutation as had been previuosly found by
Whatley et al [37]. Moreover the mutation 1043insT, pre-
viously described for 4 Argentinean patients [28,30], was
found now in 6 new apparently unrelated families.
All new mutations, except E34V as already noted, were
restricted to an individual family (Table 1) as it is the case
for most of the reported mutations in the PPOX gene.
However, there are some mutations that were detected in
more than one family. In some cases they seem to repre-
sent hot-spot mutations [27,37] but in others a founder
effect has been demonstrated [23,25,27,53]. In the
present study, from the 27 Argentinean unrelated families
studied, 10 families carried the same mutation 1043insT
(Table 1), so its prevalence in our population is about
37% (10/27), suggesting that it might represent a com-
mon mutation in Argentina. Therefore, the initial screen-
ing to elucidate the genetic defect in VP patients from
Argentina includes the insertion search. Moreover, as this
mutation has not yet been detected in VP patients from
other populations, it is very likely that the exclusive occur-
rence of 1043insT in VP families from Argentine might be
due to a founder effect. However, a T insertion one base
upstream was recently found for Swiss patients [38] sug-
gesting that perhaps it might represent a hot spot muta-
tion. Haplotype analysis is being carried out to elucidate
this question.
Conclusion
The results presented in this work asses once more that
molecular techniques represent the most accurate
approach to identify unaffected carriers. This is of vital
importance in prepubertal children in whom neither fecal
nor plasma porphyrins allow for the identification of the
VP carrier status.
Finally, although the number of individuals studied up to
now is yet limited, it appears, as it has already been found
[37] that no correlation can be established between symp-
tomatology and/or biochemical data and the type of
mutation.
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